

FINAL EXAM
DECEMBER 2016

NATIONAL BOARD OF EXAMINATIONS

PHARMACOLOGY**PAPER – I**

PHARM/D/16/34/I

Time : 3 hours

Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Define bioavailability and its clinical relevance. 5+5
b) Compare and contrast between bioequivalence and therapeutic equivalence.
2. a) What is High Throughput Screening in drug development? 5+5
b) Experimental screening methods for potential anti-arrhythmic activity of New Chemical Entity (NCE).
3. a) Compare and contrast between Therapeutic Index and Therapeutic Window. 5+(2+3)
b) Factors influencing first pass metabolism of drugs and therapeutic implication of this phenomenon.
4. a) Which are the sampling errors in drug screening program? 2+3+5
b) What is the impact of sampling errors?
c) Enumerate the ways of reducing these errors.
5. a) Principle of spectrometry technique. 5+5
b) Its utility in clinical practice with suitable examples.
6. a) Define pA₂ value. 2+4+4
b) Method of determination of pA₂ value.
c) Applications of pA₂ determination.
7. a) Targeted drug delivery. 5+5
b) Its utility in clinical practice.
8. a) Define chronopharmacology. 2+3+5
b) Aims of chronopharmacology.
c) Utility of chronopharmacology in clinical practice.
9. a) Define Good Clinical Practice (GCP) in drug development. 2+4+4
b) What are the principles of GCP?
c) Enumerate advantages of GCP.
10. a) ABC transporters. 5+5
b) Clinical relevance of these transporters.
